Lotus Pharmaceutical Co., Ltd (“Lotus” or “the Company”, Taiwan OTC ticker: 1795) announced today 2 new appointments for anticipated growth of the Company. Jaya Abraham, a leading expert in the development of first wave generics, is appointed Vice President of R&D. Zenon Zdunek is appointed Vice President of Supply Chain and Operations as he brings to Lotus more than 30 years of global supply chain and operation expertise.
Given the recent progress we have seen with our pipeline and commercial development in export markets, Jaya and Zenon join Lotus at a critical time for the Company,” said Lotus Chairman Andrew Lin. “As we take each step to execute on our long-term export and contract development and manufacturing opportunities, Jaya and Zenon bring deep and wide-ranging scientific and industry experience that will strength our competitive edge in the global arena. I look forward to working closely with them,
commented Lotus General Manager Petar Vazharov.
Jaya was General Manager of formulation and packaging at Torrent Pharmaceuticals, and she was responsible for the strategic R&D roadmap and product development of all dosage forms for global markets. Jaya is a seasoned management who has led multiple First to File projects in Zydus Cadila and other leading pharmaceuticals. Moreover, she has been involved in more than 170 generic projects, leading a team of 200 scientists to support global regulatory filings in NCE (new chemical entity), NDDS (new drug delivery system) and complex generics. Jaya holds a Master degree in Pharma from the Birla Institute of Technology and a post graduate diploma in patent laws.
Zenon brings with him tremendous experiences in international supply chain, operations, quality, R&D and engineering management in top tier pharmaceutical companies such as GSK and J&J. Additionally, he is familiar with Chinese pharmaceutical market and the management of global supply chain platforms across US, Europe and Japan. Zenon received his MBA from Duke University.